CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Oral Arsenic Trioxide (Arsenol ®)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06778187
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:42.636771+00:00
Published At: 2025-06-10T00:00:00+00:00
Record Updated At: 2025-06-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Myelodysplastic Neoplasm", "Chronic Myelomonocytic Leukemia", "TP53 Gene Mutation", "Arsenic Trioxide"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-10"
protocolSection.identificationModule.nctId: "NCT06778187"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Oral Arsenic Trioxide (Arsenol \u00ae)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.